Trials / Completed
CompletedNCT03604224
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Retrospective Observational Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Patients With BMI>25 kg/m^2, in Real World Clinical Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 178 (actual)
- Sponsor
- Johnson & Johnson Private Limited · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe clinical effectiveness of canagliflozin by mean haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2 diabetes participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canagliflozin 300 mg | Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study. |
Timeline
- Start date
- 2018-09-05
- Primary completion
- 2019-07-01
- Completion
- 2019-07-01
- First posted
- 2018-07-27
- Last updated
- 2020-08-19
Locations
3 sites across 1 country: India
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03604224. Inclusion in this directory is not an endorsement.